SCHEMBL2933784

SCHEMBL2933784

Cc1cc(C(=O)O)ccc1Nc1cncc(-c2cc3cc(F)ccc3[nH]2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 4/20 0.42
KDM4E B2RXH2 1/20 0.39
PDPK1 O15530 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
APEX1 P27695 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
FFAR1 O14842 1/20 0.38
PPARG P37231 1/20 0.38
PIK3CA P42336 3/20 0.38
PIK3CG P48736 2/20 0.38
AURKA O14965 1/20 0.37
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
CDK5 Q00535 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928690 0.89 AURKA (0.47) PIM3KDM4EPDPK1ALDH1A1LMNA
SCHEMBL2928408 0.88 PIM3 (0.46) PIM3AURKA
SCHEMBL2929192 0.79 SYK (0.40) HPGDSYK
Trifluoroacetic Acid SCHEMBL2933646 0.77 SYK (0.37) HPGDSYK
SCHEMBL2927992 0.77 ALDH1A1 (0.40) ALDH1A1HPGDTSHRAURKA
SCHEMBL2928649 0.77 PIM3 (0.39) PIM3KDM4EALDH1A1HPGDAURKA
SCHEMBL14269675 0.76 TTK (0.43)
SCHEMBL2932358 0.76 IGF1R (0.39) PIM3ALDH1A1HPGDTSHRAURKA
SCHEMBL2930667 0.76 TTK (0.41)
SCHEMBL2935136 0.75 BCL6 (0.43) PIM3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 PIM3 2131/4885KDM4E 2380/4885PDPK1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.